COLL Stock Forecast 2025-2026
Distance to COLL Price Targets
COLL Price Momentum
10 Quality Stocks Worth Considering Now
Researching Collegium Pharma (COLL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on COLL and similar high-potential opportunities.
Latest COLL Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, COLL has a bullish consensus with a median price target of $42.00 (ranging from $36.00 to $50.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $27.01, the median forecast implies a 55.5% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Oren Livnat at HC Wainwright & Co., projecting a 85.1% upside. Conversely, the most conservative target is provided by David Amsellem at Piper Sandler, suggesting a 33.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COLL Analyst Ratings
COLL Price Target Range
Latest COLL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COLL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2025 | Needham | Serge Belanger | Buy | Reiterates | $46.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $50.00 |
| Feb 4, 2025 | Piper Sandler | David Amsellem | Neutral | Maintains | $36.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $50.00 |
| Jan 10, 2025 | Needham | Serge Belanger | Buy | Upgrade | $46.00 |
| Oct 11, 2024 | Piper Sandler | David Amsellem | Neutral | Reiterates | $37.00 |
| Sep 5, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $50.00 |
| Aug 9, 2024 | Truist Securities | Les Sulewski | Buy | Maintains | $42.00 |
| Aug 9, 2024 | Needham | Serge Belanger | Hold | Reiterates | $0.00 |
| Aug 9, 2024 | Piper Sandler | David Amsellem | Neutral | Reiterates | $37.00 |
| Jul 30, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Upgrade | $47.00 |
| Jul 30, 2024 | Needham | Serge Belanger | Hold | Reiterates | $0.00 |
| Jun 7, 2024 | Jefferies | Glen Santangelo | Buy | Upgrade | $44.00 |
| May 10, 2024 | Piper Sandler | David Amsellem | Neutral | Downgrade | $39.00 |
| May 10, 2024 | Needham | Serge Belanger | Hold | Downgrade | $0.00 |
| Apr 11, 2024 | Needham | Serge Belanger | Buy | Reiterates | $40.00 |
| Feb 26, 2024 | Truist Securities | Les Sulewski | Buy | Maintains | $40.00 |
| Feb 23, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $39.00 |
| Feb 2, 2024 | Needham | Serge Belanger | Buy | Reiterates | $40.00 |
| Jan 4, 2024 | Jefferies | Glen Santangelo | Hold | Downgrade | $37.00 |
Collegium Pharmaceutical Inc. (COLL) Competitors
The following stocks are similar to Collegium Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Collegium Pharmaceutical Inc. (COLL) Financial Data
Collegium Pharmaceutical Inc. has a market capitalization of $867.88M with a P/E ratio of 14.5x. The company generates $631.45M in trailing twelve-month revenue with a 11.0% profit margin.
Revenue growth is +21.5% quarter-over-quarter, while maintaining an operating margin of +24.0% and return on equity of +32.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Collegium Pharmaceutical Inc. (COLL) Business Model
About Collegium Pharmaceutical Inc.
Develops innovative pain management medications.
Collegium Pharmaceutical generates revenue by developing and commercializing innovative medications, particularly focusing on abuse-deterrent formulations for both opioid and non-opioid treatments. The company collaborates with healthcare professionals to ensure the effective prescription and usage of its products, such as Xtampza ER, which addresses chronic pain while prioritizing patient safety.
Headquartered in Stoughton, Massachusetts, Collegium plays a critical role in the healthcare sector, particularly in addressing the opioid crisis through safer medication options. The company's commitment to innovation and responsible medication use positions it as a key player in advancing public health solutions in pain management.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
357
CEO
Mr. Vikram Karnani
Country
United States
IPO Year
2015
Website
www.collegiumpharma.comCollegium Pharmaceutical Inc. (COLL) Latest News & Analysis
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will participate in a virtual fireside chat at the 24th Annual Needham Healthcare Conference from April 7-10, 2025.
Collegium Pharmaceutical's participation in a major healthcare conference may signal potential growth opportunities, investor interest, and insights into future strategies, impacting stock performance.
Collegium Pharmaceutical (Nasdaq: COLL) will present four posters on real-world patient data from its pain portfolio at the AAPM Annual Meeting in Austin, TX, from April 3-6, 2025.
Collegium Pharmaceutical's presentation of real-world data at a major pain medicine conference could enhance credibility, attract investor interest, and potentially drive stock performance.
Gino Santini has been appointed Chairman of the Board, while Michael Heffernan and Gwen A. Melincoff will retire from the Board.
Leadership changes can impact company strategy and governance, potentially affecting stock performance and investor confidence. New leadership may bring fresh perspectives or continuity.
Collegium Pharmaceutical will present real-world data on its ADHD treatment, Jornay PM, at the NAPNAP conference in Chicago from March 10-13, 2025.
Collegium Pharmaceutical's presentations on Jornay PM could enhance its market visibility and credibility in ADHD treatment, potentially impacting stock performance and investor sentiment.
Collegium Pharmaceutical Inc. shows strong cash flow and high EBITDA margins, focusing on painkillers and ADHD drugs. The new CEO has a successful track record. Stock is currently undervalued at 4.5x EBITDA 2024.
Collegium's strong cash flow, high margins, and new CEO's successful track record signal growth potential. The undervalued stock may appreciate as product sales increase and exclusivity issues are mitigated.
Collegium Pharmaceutical (Nasdaq: COLL) will attend investor conferences on March 11-13, 2025, including those hosted by Leerink, Jefferies, and Barclays.
Collegium Pharmaceutical's participation in major investor conferences signals its commitment to transparency and growth, potentially attracting investor interest and impacting stock performance.
Frequently Asked Questions About COLL Stock
What is Collegium Pharmaceutical Inc.'s (COLL) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Collegium Pharmaceutical Inc. (COLL) has a median price target of $42.00. The highest price target is $50.00 and the lowest is $36.00.
Is COLL stock a good investment in 2025?
According to current analyst ratings, COLL has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COLL stock?
Wall Street analysts predict COLL stock could reach $42.00 in the next 12 months. This represents a 55.5% increase from the current price of $27.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Collegium Pharmaceutical Inc.'s business model?
Collegium Pharmaceutical generates revenue by developing and commercializing innovative medications, particularly focusing on abuse-deterrent formulations for both opioid and non-opioid treatments. The company collaborates with healthcare professionals to ensure the effective prescription and usage of its products, such as Xtampza ER, which addresses chronic pain while prioritizing patient safety.
What is the highest forecasted price for COLL Collegium Pharmaceutical Inc.?
The highest price target for COLL is $50.00 from Oren Livnat at HC Wainwright & Co., which represents a 85.1% increase from the current price of $27.01.
What is the lowest forecasted price for COLL Collegium Pharmaceutical Inc.?
The lowest price target for COLL is $36.00 from David Amsellem at Piper Sandler, which represents a 33.3% increase from the current price of $27.01.
What is the overall COLL consensus from analysts for Collegium Pharmaceutical Inc.?
The overall analyst consensus for COLL is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $42.00.
How accurate are COLL stock price projections?
Stock price projections, including those for Collegium Pharmaceutical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.